Table 4.
Inhibitory activity of hexavalent Nucant pseudopeptides N6, N7, and N6L in tumor cell lines of different origins.
| Cell line | Tumor cell origin | % Growth inhibition | % Cell death |
|---|---|---|---|
| After 3 days (N6/N7 - N6L) |
After 24 hours (N6/N7 - N6L) |
||
| MDA-MB 231 | Hu breast cancer | 92 - 95% | < 5% |
| MDA-MB 435 | Hu breast cancer | 58 - 66% | < 5% |
| LNCaP | Hu prostate cancer | 88 - 90% | < 5% |
| HeLa | Hu cervical cancer | 46 - 60% | < 5% |
| SW480 | Hu colon carcinoma | 25 - 35% | < 5% |
| SW620 | Hu colon carcinoma | 45 - 55% | < 5% |
| TIII | Mu melanoma cells | 55 - 83% | < 5% |
| HuT 78 | Hu cutaneous T cell leukemia | 62 - 83% | 44 - 55% |
| Jurkat | Hu T-cell leukemia | 80 - 85% | 45 - 60% |
| RAJI | Hu Burkitt lymphoma | 75 - 95% | 42 - 71% |
| HL60 | Hu acute promyelocytic leukemia | 65 - 80% | 35 - 48% |
| T29 | Mu T-cell lymphoma | 85 - 95% | 45 - 65% |
Epithelial (MDA-MB 231, MDA-MB 435, LNCaP, HeLa, SW480, SW620, TIII) and leukemia (HuT 78, Jurkat, RAJI, HL60, and T29) cell lines were cultured in the absence or presence of N6 or N7 (20 μM) or N6L (10 μM) to test their inhibitory activity on cell growth (by measuring viable cell number after 3 days of culture) and cell death (by monitoring the trypan blue uptake after 24 hours of treatment of subconfluent epithelial and freshly passaged leukemia cells). The number of viable cells in untreated control samples was used to calculate the % inhibition of cell growth and % cell death. Hu and Mu stand for human and murine origin, respectively. The mean percentage values of at least 2 independent experiments are presented.